Project Grant R43AI172705
Award Date 7/15/22
Completion Date 7/15/23
Dollars Obligated $575K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48108, USA
Similar Awards
- Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a $452,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of February 6, 2026 through January 31, 2028. This award supports in vivo profiling research for a first-in-human clinical study evaluating Chimeric Autoantibody Receptor T Cell (CAART) therapy targeting muscle-specific tyrosine kinase (MuSK)...
- Evoq Therapeutics, Inc. received a $1.05M Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 19, 2025, with completion targeted for August 31, 2027. The grant funds development and advancement of synthetic high-density lipoprotein nanodiscs—bioengineered nanotechnology platforms designed for targeted delivery of peptide antigens directly to lymph nodes to promote immune tolerance...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
- Yale University received a $373,090 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on August 25, 2025, with completion targeted for July 31, 2026. The award supports the development of Modular Degraders of Extracellular Proteins (MODES), a novel therapeutic approach designed to eliminate disease-causing extracellular proteins from circulation. Specifically, the research will...
- Project Summary The University of Michigan has received a $603,601 Project Grant award effective August 1, 2025 through July 31, 2030 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research aimed at developing novel protease inhibitors to cure chronic Toxoplasma gondii (TG) infection, a parasitic condition that causes reactivated ocular toxoplasmosis, a leading infectious cause of...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $628,373 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025, for a five-year project period extending through June 30, 2030. This Project Grant supports fundamental and translational research focused on understanding the immunobiology of conventional dendritic cells (CDC1) and their...
- This Project Grant award of $1,152,284 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports fundamental research investigating the molecular and genetic regulation of myelin formation in the central nervous system (CNS). Awarded to Oregon Health & Science University on June 19, 2025, with completion anticipated by March 31, 2030, the grant funds research focused...